These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8172821)

  • 1. Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomas.
    Magrath IT
    Ann Oncol; 1994; 5 Suppl 1():67-70. PubMed ID: 8172821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense therapy for lymphomas.
    Cotter FE
    Hematol Oncol; 1997 Feb; 15(1):3-11. PubMed ID: 9378470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy in non-Hodgkin's lymphomas (author's transl)].
    Schmidt CG
    Strahlentherapie; 1977 May; 153(5):283-92. PubMed ID: 69343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the management of non-Hodgkin's lymphomas.
    Gaynor ER; Fisher RI
    Dis Mon; 1989 Sep; 35(9):597-650. PubMed ID: 2676434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
    Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
    Klasa RJ
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
    Yildiz D; Oztas H; Hilal Ates B
    Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current status of chemotherapy in the treatment of malignant lymphomas].
    Ohnoshi T; Hayashi K; Ueno K; Tada A; Murashima M; Mizuta J; Tagawa S; Kimura I
    Gan To Kagaku Ryoho; 1989 May; 16(5):1989-96. PubMed ID: 2658838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
    Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
    Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
    Klasa RJ; Bally MB; Ng R; Goldie JH; Gascoyne RD; Wong FM
    Clin Cancer Res; 2000 Jun; 6(6):2492-500. PubMed ID: 10873104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense therapy of hematologic malignancies.
    Cotter FE
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):9-14. PubMed ID: 10530711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphomas: the impact of chemotherapy on survival.
    Gore ME; McElwain TJ
    Cancer Surv; 1989; 8(3):647-70. PubMed ID: 2701086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The present status of therapeutic possibilities in malignant lymphomas].
    Klener P
    Cas Lek Cesk; 1993 May; 132(9):261-5. PubMed ID: 8513471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.